{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:40:53Z","timestamp":1767836453553,"version":"3.49.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Behav. Neurosci."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The current study investigates sex differences associated with pharmacological and demographic characteristics in Alzheimer patients (AD) with dementia (ADD) or mild cognitive impairment (MCI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A retrospective analytical approach was used to analyze data from 45,696 AD patients with MCI or ADD. The univariate analysis was used to determine differences in demographic, and pharmacological characteristics for male and female ADD and MCI-AD patients. Multivariate analysis was used to predict specific pharmacological and demographic factors that are associated with male and female MCI and ADD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>In the adjusted analysis for male patients, Hispanics [0.166,0.020 \u2013 1.355, <jats:italic>P<\/jats:italic> = 0.094] or African Americans [OR = 2.380, 95% CI,2.120 \u2013 2.674, <jats:italic>P<\/jats:italic> &amp;lt; 0.001], were more likely to have MCI-AD and be treated with galantamine [OR = 0.559, 95% CI, 0.382 \u2013 0.818, <jats:italic>P<\/jats:italic> = 0.003], donepezil [OR = 1.639, 95% CI,1.503 \u2013 1.787, <jats:italic>P<\/jats:italic> &amp;lt; 0.001], rivastigmine [OR = 1.394, 95% CI,1.184 \u2013 1.642, <jats:italic>P<\/jats:italic> &amp;lt; 0.001], olanzapine [OR = 2.727, 95% CI,2.315 \u2013 3.212, <jats:italic>P<\/jats:italic> &amp;lt; 0.001], risperidone [OR = 2.973, 95% CI,2.506 \u2013 3.526, <jats:italic>P<\/jats:italic> &amp;lt; 0.001], present with increasing age [1.075,1.071 \u2013 1.079, <jats:italic>P<\/jats:italic> &amp;lt; 0.001], and are on tobacco use [OR = 1.150, 95% CI,1.054 \u2013 1.254, <jats:italic>P<\/jats:italic> = 0.002]. For female patients, buspirone [OR = 0.767, 95% CI, 0.683 \u2013 0.861, <jats:italic>P<\/jats:italic> &amp;lt; 0.001] and a history of alcohol (ETOH) use [OR = 0.484, 95% CI, 0.442 \u2013 0.529, <jats:italic>P<\/jats:italic> &amp;lt; 0.001] were associated with MCI-AD. Increasing age [OR = 1.096, 95% CI, 1.093 \u2013 1.100, <jats:italic>P<\/jats:italic> &amp;lt; 0.001], donepezil [OR = 2.185, 95% CI, 2.035 \u2013 2.346, <jats:italic>P<\/jats:italic> &amp;lt; 0.001], memantine [OR = 2.283, 95% CI, 2.104 \u2013 2.477, <jats:italic>P<\/jats:italic> &amp;lt; 0.001] aripiprazole [OR = 1.807, 95% CI, 1.544 \u2013 2.113, <jats:italic>P<\/jats:italic> &amp;lt; 0.001] olanzapine [OR = 2.289, 95% CI, 1.986 \u2013 2.640, <jats:italic>P<\/jats:italic> &amp;lt; 0.001] risperidone [OR = 2.548, 95% CI, 2.246 \u2013 2.889, <jats:italic>P<\/jats:italic> &amp;lt; 0.001] buspirone [OR = 0.767, 95% CI, 0.683 \u2013 0.861, <jats:italic>P<\/jats:italic> &amp;lt; 0.001] escitalopram [OR = 1.213, 95% CI,1.119 \u2013 1.315, <jats:italic>P<\/jats:italic> &amp;lt; 0.001] African Americans [OR = 1.395, 95% CI, 1.268 \u2013 1.535, <jats:italic>P<\/jats:italic> &amp;lt; 0.001] and tobacco use [OR = 1.150, 95% CI, 1.073 \u2013 1.233, <jats:italic>P<\/jats:italic> &amp;lt; 0.001] were associated with ADD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings reveal that MCI-AD patients were more likely to be Hispanics or African American males treated with rivastigmine, olanzapine and citalopram. African American females were associated with ADD and more likely to be treated with buspirone and presented with a history of ETOH. This finding suggests the need for a pharmacological treatment approach encompassing sex-sensitive strategies for MCI-AD and ADD patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnbeh.2022.828782","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:27:19Z","timestamp":1648819639000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Sex Differences in Demographic and Pharmacological Factors in Alzheimer Patients With Dementia and Cognitive Impairments"],"prefix":"10.3389","volume":"16","author":[{"given":"Oreoluwa O.","family":"Coker-Ayo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel I.","family":"Nathaniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Poupore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa J.","family":"Bailey-Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie Theriot","family":"Roley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard L.","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooks","family":"McPhail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Russ-Sellers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas I.","family":"Nathaniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-132273","article-title":"Gender differences in demographic and pharmacological factors in patients diagnosed with late-onset of Alzheimer\u2019s Disease.","volume":"12","author":"Bailey-Taylor","year":"2022","journal-title":"Brain Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1037\/tra0000774","article-title":"Psychological sequelae of social isolation and loneliness might be a larger problem in young adults than older adults.","volume":"12","author":"Beam","year":"2020","journal-title":"Psychol. Trauma"},{"key":"B3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11002-014-9299-9","article-title":"How collinearity affects mixture regression results.","volume":"26","author":"Becker","year":"2015","journal-title":"Mark. Lett."},{"key":"B4","first-page":"529","article-title":"Gender differences in pharmacokinetics and pharmacodynamics.","volume":"37","author":"Beierle","year":"1999","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B5","first-page":"303","article-title":"Donepezil in Alzheimer\u2019s disease: from conventional trials to pharmacogenetics.","volume":"3","author":"Cacabelos","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B6","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.trci.2018.08.009","article-title":"Racial and ethnic differences in trends in dementia prevalence and risk factors in the United States.","volume":"4","author":"Chen","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40501-017-0102-4","article-title":"Pharmacological management of anxiety disorders in the elderly.","volume":"4","author":"Crocco","year":"2017","journal-title":"Curr. Treat. Options Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0457-9","article-title":"Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer\u2019s disease: a network meta-analysis of 41 randomized controlled trials.","volume":"10","author":"Dou","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria.","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrneurol.2009.215","article-title":"The clinical use of structural MRI in Alzheimer disease.","volume":"6","author":"Frisoni","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-021-03327-7","article-title":"Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil.","volume":"21","author":"Fulone","year":"2021","journal-title":"BMC Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/archpsyc.64.10.1115","article-title":"Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: Is it a practice effect?","volume":"64","author":"Goldberg","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3233\/JAD-180903","article-title":"Present algorithms and future treatments for Alzheimer\u2019s disease.","volume":"67","author":"Grossberg","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"B14","first-page":"211","article-title":"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis.","volume":"3","author":"Hansen","year":"2008","journal-title":"Clin. Interv. Aging."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","article-title":"Alzheimer disease in the United States (2010-2050) estimated using the 2010 census.","volume":"80","author":"Hebert","year":"2013","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.18865\/ed.25.3.245","article-title":"The national institute on aging health disparities research framework.","volume":"25","author":"Hill","year":"2015","journal-title":"Ethn. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1586\/ern.09.143","article-title":"Effect of second-generation antipsychotics on cognition: current issues and future challenges.","volume":"10","author":"Hill","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"B18","first-page":"747","article-title":"Cholinesterase Inhibitors for Alzheimer\u2019s Disease.","volume":"74","author":"Hitzeman","year":"2006","journal-title":"Am. Fam. Physician"},{"key":"B19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00023210-200115050-00004","article-title":"Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer\u2019s disease.","volume":"15","author":"Imbimbo","year":"2001","journal-title":"CNS Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/gps.1038","article-title":"A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer\u2019s disease.","volume":"19","author":"Jones","year":"2004","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3233\/JAD-161118","article-title":"Therapeutics of neurotransmitters in Alzheimer\u2019s disease.","volume":"57","author":"Kandimalla","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"B22","first-page":"102","article-title":"Pharmacological treatment of mild cognitive impairment as a prodromal syndrome of Alzheimer\u2019s disease.","volume":"11","author":"Karakaya","year":"2013","journal-title":"Curr. Neuropharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.mayocp.2014.06.019","article-title":"Mild cognitive impairment and mild dementia: a clinical perspective.","volume":"89","author":"Knopman","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/15360288.2017.1279500","article-title":"Donepezil, an acetylcholinesterase inhibitor, can attenuate gabapentinoid-induced somnolence in patients with neuropathic pain: a retrospective chart review.","volume":"31","author":"Kogure","year":"2017","journal-title":"J. Pain Palliat. Care Pharmacother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/ndt.s6411","article-title":"Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole.","volume":"6","author":"Kohen","year":"2010","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamainternmed.2016.6807","article-title":"A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012.","volume":"177","author":"Langa","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1001\/jama.2014.13806","article-title":"The diagnosis and management of mild cognitive impairment: a clinical review.","volume":"312","author":"Langa","year":"2014","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5498\/wjp.v6.i1.54","article-title":"Sex differences in cognitive impairment in Alzheimer\u2019s disease.","volume":"6","author":"Laws","year":"2016","journal-title":"World J. Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00472","article-title":"Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease.","volume":"13","author":"Li","year":"2019","journal-title":"Front. Neurosci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.trci.2015.07.001","article-title":"Marked gender differences in progression of mild cognitive impairment over 8 years.","volume":"1","author":"Lin","year":"2015","journal-title":"Alzheimers Dement."},{"key":"B31","first-page":"65","article-title":"The borderland between normal aging and dementia.","volume":"29","author":"Lo","year":"2017","journal-title":"Ci Ji Yi Xue Za Zhi"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-020-01948-3","article-title":"Prevalence of mild cognitive impairment in community-dwelling Chinese populations aged over 55years: a meta-analysis and systematic review.","volume":"21","author":"Lu","year":"2021","journal-title":"BMC Geriatr."},{"key":"B33","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3233\/JAD-190546","article-title":"Efficacy and Safety of Cholinesterase Inhibitors for Mild Cognitive Impairment:A Systematic Review and Meta-Analysis.","volume":"71","author":"Matsunaga","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"B34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/1673-5374.264445","article-title":"Selective serotonin reuptake inhibitors and Alzheimer\u2019s disease.","volume":"15","author":"Mdawar","year":"2020","journal-title":"Neural Regen. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1161\/01.CIR.0000158136.76824.04","article-title":"State of disparities in cardiovascular health in the United States.","volume":"111","author":"Mensah","year":"2005","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/CLEP.S37929","article-title":"Clinical epidemiology of Alzheimer\u2019s disease: assessing sex and gender differences.","volume":"6","author":"Mielke","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","article-title":"Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer\u2019s disease.","volume":"24","author":"Parsons","year":"2013","journal-title":"Neurotox. Res."},{"key":"B38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1081\/CBI-120021384","article-title":"Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers.","volume":"20","author":"P\u00e9rez","year":"2003","journal-title":"Chronobiol. Int."},{"key":"B39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/pgmj.2005.036665","article-title":"Ageing and the brain.","volume":"82","author":"Peters","year":"2006","journal-title":"Postgrad. Med. J."},{"key":"B40","first-page":"404","article-title":"Mild cognitive impairment.","volume":"22","author":"Petersen","year":"2016","journal-title":"Continuum"},{"key":"B41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","article-title":"Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): clinical characterization.","volume":"74","author":"Petersen","year":"2010","journal-title":"Neurology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome.","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch. Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neurobiolaging.2014.10.031","article-title":"Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer\u2019s type.","volume":"36","author":"Popp","year":"2015","journal-title":"Neurobiol. Aging."},{"key":"B44","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/s1474-4422(03)00502-7","article-title":"Treatment of Alzheimer\u2019s disease: current status and new perspectives.","volume":"2","author":"Scarpini","year":"2003","journal-title":"Lancet Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1176\/appi.ajp.161.8.1324","article-title":"Gender differences in the prescribing of antipsychotic drugs.","volume":"161","author":"Seeman","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.05.008","article-title":"Men and women respond differently to antipsychotic drugs.","volume":"163","author":"Seeman","year":"2020","journal-title":"Neuropharmacology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00221-013-3818-4","article-title":"The role of serotonin in memory: interactions with neurotransmitters and downstream signaling.","volume":"232","author":"Seyedabadi","year":"2014","journal-title":"Exp. Brain Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.pneurobio.2016.04.001","article-title":"Monoaminergic neuropathology in Alzheimer\u2019s disease.","volume":"151","author":"\u0160imi\u0107","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/biom10010040","article-title":"Alzheimer\u2019s disease pharmacotherapy in relation to cholinergic system involvement.","volume":"10","author":"Stanciu","year":"2020","journal-title":"Biomolecules"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/14656566.2018.1491966","article-title":"Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review.","volume":"19","author":"Strawn","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006148","article-title":"The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment.","volume":"2","author":"Tarawneh","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe alzheimer disease already receiving donepezila randomized controlled trial.","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1503\/cmaj.130451","article-title":"Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.","volume":"185","author":"Tricco","year":"2013","journal-title":"CMAJ Can. Med. Assoc. J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1176\/appi.ajp.2011.08121844","article-title":"Cognitive effects of atypical antipsychotic medications in patients with Alzheimer\u2019s disease: outcomes from CATIE-AD.","volume":"168","author":"Vigen","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"B55","doi-asserted-by":"publisher","first-page":"S527","DOI":"10.3233\/JAD-2010-100501","article-title":"Why women have more Alzheimer\u2019s disease than men: gender and mitochondrial toxicity of amyloid-beta peptide.","volume":"20","author":"Vi\u00f1a","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0064-7","article-title":"The effect of selective serotonin reuptake inhibitors on cognitive function in patients with Alzheimer\u2019s disease and vascular dementia: focusing on fluoxetine with long follow-up periods.","volume":"4","author":"Xie","year":"2019","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Frontiers in Behavioral Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnbeh.2022.828782\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:27:36Z","timestamp":1648819656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnbeh.2022.828782\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":56,"alternative-id":["10.3389\/fnbeh.2022.828782"],"URL":"https:\/\/doi.org\/10.3389\/fnbeh.2022.828782","relation":{},"ISSN":["1662-5153"],"issn-type":[{"value":"1662-5153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"article-number":"828782"}}